potentially 250M4 Sep 2014 18:32
"Benchmark Holdings PLC, the international animal health, technical publishing and sustainability science business, announces that its Animal Health division has entered into an agreement with HypoPet AG ("HypoPet"), a Swiss research company based at the University of Zurich, for the final commercialisation, manufacture and distribution of a breakthrough vaccine for cats, HypoCat®, which neutralises the Fel d 1 protein, the primary cause of human allergic reaction to cats.
With an estimated 10% of the global population suffering from cat allergies, the agreement between HypoPet and Benchmark is designed to open up a new market within the animal health sector with an estimated global value of £250 million. Benchmark's world-class vaccine manufacturing facilities in Braintree and Edinburgh, combined with its proven vaccine and process development experience puts it in an ideal position to develop and commercialise this innovative new vaccine."